OBJECTIVE: Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is associated with an increased risk of systemic lupus erythematosus (SLE). PTPN22 encodes Lyp, and a disease-associated coding variant bears an R620W substitution (LypW). LypW carriage is associated with impaired production of type I interferon (IFN) by myeloid cells following Toll-like receptor (TLR) engagement. The aim of this study was to investigate the effects of LypW carriage on TLR signaling in patients with SLE. METHODS: Plasma IFNα concentrations and whole-blood IFN gene scores were compared in SLE patients who were LypW carriers and those who were noncarriers. TLR-7 agonist R848-stimulated IFNα and tumor necrosis factor levels, IFN-dependent gene expression, and STAT-1 activation were determined in peripheral blood mononuclear cells (PBMCs) and/or plasmacytoid dendritic cells (PDCs) obtained from these patients. The effect of LypW expression on the systemic type I IFN response to R848 stimulation in vivo was assessed in transgenic mice. RESULTS: Plasma IFNα levels and whole-blood IFN gene signatures were comparable in SLE patients who were LypW carriers and those who were noncarriers. However, PBMCs from LypW carriers produced less IFNα and showed reduced IFN-dependent gene up-regulation and STAT-1 activation after R848 stimulation. The frequency of PDCs producing IFNα2 and the per-cell IFNα2 levels were significantly reduced in LypW carriers. LypW-transgenic mice displayed reduced TLR-7-induced circulating type I IFN responses. CONCLUSION: PDCs from SLE patients carrying the disease-associated PTPN22 variant LypW showed a reduced capacity for TLR-7 agonist-induced type I IFN production, even though LypW carriers displayed systemic type I IFN activation comparable with that observed in noncarriers. LypW carriage identifies SLE patients who may harbor defects in TLR- and PDC-dependent host defense or antiinflammatory functions.
OBJECTIVE:Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is associated with an increased risk of systemic lupus erythematosus (SLE). PTPN22 encodes Lyp, and a disease-associated coding variant bears an R620W substitution (LypW). LypW carriage is associated with impaired production of type I interferon (IFN) by myeloid cells following Toll-like receptor (TLR) engagement. The aim of this study was to investigate the effects of LypW carriage on TLR signaling in patients with SLE. METHODS: Plasma IFNα concentrations and whole-blood IFN gene scores were compared in SLEpatients who were LypW carriers and those who were noncarriers. TLR-7 agonist R848-stimulated IFNα and tumor necrosis factor levels, IFN-dependent gene expression, and STAT-1 activation were determined in peripheral blood mononuclear cells (PBMCs) and/or plasmacytoid dendritic cells (PDCs) obtained from these patients. The effect of LypW expression on the systemic type I IFN response to R848 stimulation in vivo was assessed in transgenic mice. RESULTS: Plasma IFNα levels and whole-blood IFN gene signatures were comparable in SLEpatients who were LypW carriers and those who were noncarriers. However, PBMCs from LypW carriers produced less IFNα and showed reduced IFN-dependent gene up-regulation and STAT-1 activation after R848 stimulation. The frequency of PDCs producing IFNα2 and the per-cell IFNα2 levels were significantly reduced in LypW carriers. LypW-transgenic mice displayed reduced TLR-7-induced circulating type I IFN responses. CONCLUSION: PDCs from SLEpatients carrying the disease-associated PTPN22 variant LypW showed a reduced capacity for TLR-7 agonist-induced type I IFN production, even though LypW carriers displayed systemic type I IFN activation comparable with that observed in noncarriers. LypW carriage identifies SLEpatients who may harbor defects in TLR- and PDC-dependent host defense or antiinflammatory functions.
Authors: Peter K Gregersen; Gila Klein; Mary Keogh; Marlena Kern; Margaret DeFranco; Kim R Simpfendorfer; Sun Jung Kim; Betty Diamond Journal: Immunol Res Date: 2015-12 Impact factor: 2.829
Authors: Juliet N Crabtree; Wenqian He; Weihua Guan; Mark Flage; Matthew S Miller; Erik J Peterson Journal: J Infect Dis Date: 2016-03-30 Impact factor: 5.226
Authors: Marianne R Spalinger; Stephanie Kasper; Claudia Gottier; Silvia Lang; Kirstin Atrott; Stephan R Vavricka; Sylvie Scharl; Tina Raselli; Isabelle Frey-Wagner; Petrus M Gutte; Markus G Grütter; Hans-Dietmar Beer; Emmanuel Contassot; Andrew C Chan; Xuezhi Dai; David J Rawlings; Florian Mair; Burkhard Becher; Werner Falk; Michael Fried; Gerhard Rogler; Michael Scharl Journal: J Clin Invest Date: 2016-04-04 Impact factor: 14.808
Authors: Daniel J Perry; Leeana D Peters; Priya Saikumar Lakshmi; Lin Zhang; Zhao Han; Clive H Wasserfall; Clayton E Mathews; Mark A Atkinson; Todd M Brusko Journal: J Immunol Date: 2021-07-23 Impact factor: 5.426